Replies to post #1511 on EPS & Earnings ... Hits & Misses

[madrose1]

Sepracor to shine-BusinessWeek
From the "Inside Wall Street" section: Sentiment is divided on Wall Street regarding Sepracor (SEPR), best known for its sleep drug, Lunesta. BMO Capital Market's Robert Hazlett says the gloom and doom is overdone regarding SEPR, he thinks the stock will hit $68 in 12-18 months, and argues that the company is going to be more profitable than analysts estimate.